See the DrugPatentWatch profile for Agrylin
What is Agrylin used for?
Agrylin is the brand name for anagrelide, a medicine used to reduce an abnormally high platelet count (thrombocytosis), most commonly in conditions like essential thrombocythemia. The goal is to lower the risk of complications that can come with high platelets, such as clotting or bleeding problems [1].
How does Agrylin work?
Anagrelide works by affecting the production and maturation of blood platelets. It slows platelet production in the bone marrow, which leads to a decrease in platelet counts [1].
How is Agrylin typically taken?
Dosing depends on the condition being treated and how a patient responds. Clinicians usually start at a dose and adjust based on platelet counts and tolerability, with regular blood tests during treatment [1].
What are common side effects people ask about?
Side effects can vary by patient, but anagrelide has been associated with blood-pressure changes and cardiovascular effects, as well as headaches, palpitations, and fluid retention. Because it can affect the heart and circulation, prescribers often monitor patients more closely if they have existing heart disease or cardiovascular risk [1].
What risks matter most, and when should someone call a doctor?
Patients are generally advised to seek medical attention promptly if they develop symptoms that could suggest cardiovascular problems (for example, chest pain, fainting, or severe shortness of breath), since anagrelide can influence heart rate and blood pressure. Close monitoring of blood counts is also important to avoid excessive reduction in platelets [1].
Is Agrylin still available and what alternatives exist?
Whether Agrylin is available can depend on country and prescribing rules. In many places, anagrelide is also available as a generic, and treatment for high platelet counts may also include other medications depending on the diagnosis and risk level (for example, therapies targeting clotting risk). Your clinician can recommend options based on your specific condition and risk profile [1].
Sources
[1] https://www.drugs.com/agrylin.html